TGR5在非酒精性脂肪性肝病中的研究进展
Research Progress of TGR5 in Non-Alcoholic Fatty Liver Disease
DOI: 10.12677/acm.2026.1662241, PDF,   
作者: 廖家豪：赣南医科大学第一临床医学院，江西 赣州；谢 军*：赣南医科大学第一附属医院消化内科，江西 赣州
关键词: 非酒精性脂肪性肝病；胆汁酸代谢；TGR5；TGR5激动剂；Non-Alcoholic Fatty Liver Disease； Bile Acid Metabolism； TGR5； TGR5 Agonist
摘要: 非酒精性脂肪性肝病(NAFLD)是全球范围内最为常见的慢性肝病，可从单纯性脂肪肝逐步发展为肝纤维化进而引发肝硬化。虽然我们对这一疾病的认知不断深入，但临床上尚缺乏有效的靶向治疗药物。Takeda G蛋白偶联受体5 (TGR5)作为胆汁酸信号传导过程中的关键膜受体，参与了机体的能量代谢、胰岛素敏感性以及炎症反应的调节与调控，这些生理过程恰恰与非酒精性脂肪性肝病的发生发展环环相扣，现已成为该领域的研究热点。本文系统综述了TGR5在NAFLD中的作用机制及药物的研发进展，希望为临床防治这一疾病拓展新的思路。
Abstract: Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease worldwide. It can gradually progress from simple fatty liver to liver fibrosis and eventually to cirrhosis. Despite our increasing understanding of this disease, effective targeted therapies remain lacking in clinical practice. Takeda G protein-coupled receptor 5 (TGR5), a key membrane receptor in bile acid signaling, participates in regulating energy metabolism, insulin sensitivity, and inflammatory responses, which are closely linked to the development and progression of NAFLD. Accordingly, TGR5 has become a research hotspot in this field. This article systematically reviews the mechanism of TGR5 in NAFLD and the research progress of its targeted drugs, aiming to provide new insights for the clinical prevention and treatment of NAFLD.
文章引用：廖家豪, 谢军. TGR5在非酒精性脂肪性肝病中的研究进展[J]. 临床医学进展, 2026, 16(6): 468-480. https://doi.org/10.12677/acm.2026.1662241

参考文献

[1] Nassir, F. (2022) NAFLD: Mechanisms, Treatments, and Biomarkers. Biomolecules, 12, Article No. 824. [Google Scholar] [CrossRef] [PubMed]
[2] Zhou, J., Zhou, F., Wang, W., Zhang, X., Ji, Y., Zhang, P., et al. (2020) Epidemiological Features of NAFLD from 1999 to 2018 in China. Hepatology, 71, 1851-1864. [Google Scholar] [CrossRef] [PubMed]
[3] Han, S.K., Baik, S.K. and Kim, M.Y. (2023) Non-Alcoholic Fatty Liver Disease: Definition and Subtypes. Clinical and Molecular Hepatology, 29, S5-S16. [Google Scholar] [CrossRef] [PubMed]
[4] Buzzetti, E., Pinzani, M. and Tsochatzis, E.A. (2016) The Multiple-Hit Pathogenesis of Non-Alcoholic Fatty Liver Disease (NAFLD). Metabolism, 65, 1038-1048. [Google Scholar] [CrossRef] [PubMed]
[5] Rong, L., Zou, J., Ran, W., Qi, X., Chen, Y., Cui, H., et al. (2023) Advancements in the Treatment of Non-Alcoholic Fatty Liver Disease (NAFLD). Frontiers in Endocrinology, 13, Article 1087260. [Google Scholar] [CrossRef] [PubMed]
[6] Chiang, J.Y.L. and Ferrell, J.M. (2020) Bile Acid Receptors FXR and TGR5 Signaling in Fatty Liver Diseases and Therapy. American Journal of Physiology-Gastrointestinal and Liver Physiology, 318, G554-G573. [Google Scholar] [CrossRef] [PubMed]
[7] Kawamata, Y., Fujii, R., Hosoya, M., Harada, M., Yoshida, H., Miwa, M., et al. (2003) A G Protein-Coupled Receptor Responsive to Bile Acids. Journal of Biological Chemistry, 278, 9435-9440. [Google Scholar] [CrossRef] [PubMed]
[8] Wang, X.X., Xie, C., Libby, A.E., Ranjit, S., Levi, J., Myakala, K., et al. (2022) The Role of FXR and TGR5 in Reversing and Preventing Progression of Western Diet-Induced Hepatic Steatosis, Inflammation, and Fibrosis in Mice. Journal of Biological Chemistry, 298, Article ID: 102530. [Google Scholar] [CrossRef] [PubMed]
[9] Thomas, C., Gioiello, A., Noriega, L., Strehle, A., Oury, J., Rizzo, G., et al. (2009) TGR5-Mediated Bile Acid Sensing Controls Glucose Homeostasis. Cell Metabolism, 10, 167-177. [Google Scholar] [CrossRef] [PubMed]
[10] Katsuma, S., Hirasawa, A. and Tsujimoto, G. (2005) Bile Acids Promote Glucagon-Like Peptide-1 Secretion through TGR5 in a Murine Enteroendocrine Cell Line STC-1. Biochemical and Biophysical Research Communications, 329, 386-390. [Google Scholar] [CrossRef] [PubMed]
[11] Guo, C., Xie, S., Chi, Z., Zhang, J., Liu, Y., Zhang, L., et al. (2016) Bile Acids Control Inflammation and Metabolic Disorder through Inhibition of NLRP3 Inflammasome. Immunity, 45, 802-816. [Google Scholar] [CrossRef] [PubMed]
[12] Shi, Y., Su, W., Zhang, L., Shi, C., Zhou, J., Wang, P., et al. (2021) TGR5 Regulates Macrophage Inflammation in Nonalcoholic Steatohepatitis by Modulating NLRP3 Inflammasome Activation. Frontiers in Immunology, 11, Article 609060. [Google Scholar] [CrossRef] [PubMed]
[13] Maruyama, T., Miyamoto, Y., Nakamura, T., Tamai, Y., Okada, H., Sugiyama, E., et al. (2002) Identification of Membrane-Type Receptor for Bile Acids (M-BAR). Biochemical and Biophysical Research Communications, 298, 714-719. [Google Scholar] [CrossRef] [PubMed]
[14] Tiwari, A. and Maiti, P. (2009) TGR5: An Emerging Bile Acid G-Protein-Coupled Receptor Target for the Potential Treatment of Metabolic Disorders. Drug Discovery Today, 14, 523-530. [Google Scholar] [CrossRef] [PubMed]
[15] Holter, M.M., Chirikjian, M.K., Govani, V.N. and Cummings, B.P. (2020) TGR5 Signaling in Hepatic Metabolic Health. Nutrients, 12, Article No. 2598. [Google Scholar] [CrossRef] [PubMed]
[16] Watanabe, M., Houten, S.M., Mataki, C., Christoffolete, M.A., Kim, B.W., Sato, H., et al. (2006) Bile Acids Induce Energy Expenditure by Promoting Intracellular Thyroid Hormone Activation. Nature, 439, 484-489. [Google Scholar] [CrossRef] [PubMed]
[17] Broeders, E.P.M., Nascimento, E.B.M., Havekes, B., Brans, B., Roumans, K.H.M., Tailleux, A., et al. (2015) The Bile Acid Chenodeoxycholic Acid Increases Human Brown Adipose Tissue Activity. Cell Metabolism, 22, 418-426. [Google Scholar] [CrossRef] [PubMed]
[18] Jensen, D.D., Godfrey, C.B., Niklas, C., Canals, M., Kocan, M., Poole, D.P., et al. (2013) The Bile Acid Receptor TGR5 Does Not Interact with β-Arrestins or Traffic to Endosomes but Transmits Sustained Signals from Plasma Membrane Rafts. Journal of Biological Chemistry, 288, 22942-22960. [Google Scholar] [CrossRef] [PubMed]
[19] Velazquez-Villegas, L.A., Perino, A., Lemos, V., Zietak, M., Nomura, M., Pols, T.W.H., et al. (2018) TGR5 Signalling Promotes Mitochondrial Fission and Beige Remodelling of White Adipose Tissue. Nature Communications, 9, Article No. 245. [Google Scholar] [CrossRef] [PubMed]
[20] Hu, M., He, W., Gao, P., Yang, Q., He, K., Cao, L., et al. (2019) Virus-Induced Accumulation of Intracellular Bile Acids Activates the TGR5-β-Arrestin-Src Axis to Enable Innate Antiviral Immunity. Cell Research, 29, 193-205. [Google Scholar] [CrossRef] [PubMed]
[21] Perino, A., Demagny, H., Velazquez-Villegas, L. and Schoonjans, K. (2021) Molecular Physiology of Bile Acid Signaling in Health, Disease, and Aging. Physiological Reviews, 101, 683-731. [Google Scholar] [CrossRef] [PubMed]
[22] Hofmann, A.F. and Hagey, L.R. (2008) Bile Acids: Chemistry, Pathochemistry, Biology, Pathobiology, and Therapeutics. Cellular and Molecular Life Sciences, 65, 2461-2483. [Google Scholar] [CrossRef] [PubMed]
[23] Hofmann, A.F., Hagey, L.R. and Krasowski, M.D. (2010) Bile Salts of Vertebrates: Structural Variation and Possible Evolutionary Significance. Journal of Lipid Research, 51, 226-246. [Google Scholar] [CrossRef] [PubMed]
[24] Russell, D.W. (2003) The Enzymes, Regulation, and Genetics of Bile Acid Synthesis. Annual Review of Biochemistry, 72, 137-174. [Google Scholar] [CrossRef] [PubMed]
[25] Keitel, V., Cupisti, K., Ullmer, C., Knoefel, W.T., Kubitz, R. and Häussinger, D. (2009) The Membrane-Bound Bile Acid Receptor TGR5 Is Localized in the Epithelium of Human Gallbladders. Hepatology, 50, 861-870. [Google Scholar] [CrossRef] [PubMed]
[26] Keitel, V., Ullmer, C. and Häussinger, D. (2010) The Membrane-Bound Bile Acid Receptor TGR5 (Gpbar-1) Is Localized in the Primary Cilium of Cholangiocytes. Biological Chemistry, 391, 785-789. [Google Scholar] [CrossRef] [PubMed]
[27] Merlen, G., Kahale, N., Ursic-Bedoya, J., Bidault-Jourdainne, V., Simerabet, H., Doignon, I., et al. (2019) TGR5-Dependent Hepatoprotection through the Regulation of Biliary Epithelium Barrier Function. Gut, 69, 146-157. [Google Scholar] [CrossRef] [PubMed]
[28] McGavigan, A.K., Garibay, D., Henseler, Z.M., Chen, J., Bettaieb, A., Haj, F.G., et al. (2015) TGR5 Contributes to Glucoregulatory Improvements after Vertical Sleeve Gastrectomy in Mice. Gut, 66, 226-234. [Google Scholar] [CrossRef] [PubMed]
[29] Pathak, P., Liu, H., Boehme, S., Xie, C., Krausz, K.W., Gonzalez, F., et al. (2017) Farnesoid X Receptor Induces Takeda G-Protein Receptor 5 Cross-Talk to Regulate Bile Acid Synthesis and Hepatic Metabolism. Journal of Biological Chemistry, 292, 11055-11069. [Google Scholar] [CrossRef] [PubMed]
[30] Maruyama, T., Tanaka, K., Suzuki, J., Miyoshi, H., Harada, N., Nakamura, T., et al. (2006) Targeted Disruption of G Protein-Coupled Bile Acid Receptor 1 (Gpbar1/M-Bar) in Mice. Journal of Endocrinology, 191, 197-205. [Google Scholar] [CrossRef] [PubMed]
[31] Pols, T.W.H., Noriega, L.G., Nomura, M., Auwerx, J. and Schoonjans, K. (2011) The Bile Acid Membrane Receptor TGR5 as an Emerging Target in Metabolism and Inflammation. Journal of Hepatology, 54, 1263-1272. [Google Scholar] [CrossRef] [PubMed]
[32] Fiorucci, S., Distrutti, E., Carino, A., Zampella, A. and Biagioli, M. (2021) Bile Acids and Their Receptors in Metabolic Disorders. Progress in Lipid Research, 82, Article ID: 101094. [Google Scholar] [CrossRef] [PubMed]
[33] Chen, J. and Vitetta, L. (2020) Gut Microbiota Metabolites in NAFLD Pathogenesis and Therapeutic Implications. International Journal of Molecular Sciences, 21, Article No. 5214. [Google Scholar] [CrossRef] [PubMed]
[34] Kumar, D.P., Asgharpour, A., Mirshahi, F., Park, S.H., Liu, S., Imai, Y., et al. (2016) Activation of Transmembrane Bile Acid Receptor TGR5 Modulates Pancreatic Islet Α Cells to Promote Glucose Homeostasis. Journal of Biological Chemistry, 291, 6626-6640. [Google Scholar] [CrossRef] [PubMed]
[35] Lewis, N.D., Patnaude, L.A., Pelletier, J., Souza, D.J., Lukas, S.M., King, F.J., et al. (2014) A GPBAR1 (TGR5) Small Molecule Agonist Shows Specific Inhibitory Effects on Myeloid Cell Activation in Vitro and Reduces Experimental Autoimmune Encephalitis (EAE) in Vivo. PLOS ONE, 9, e100883. [Google Scholar] [CrossRef] [PubMed]
[36] Keitel, V., Donner, M., Winandy, S., Kubitz, R. and Häussinger, D. (2008) Expression and Function of the Bile Acid Receptor TGR5 in Kupffer Cells. Biochemical and Biophysical Research Communications, 372, 78-84. [Google Scholar] [CrossRef] [PubMed]
[37] Ma, K., Tang, D., Yu, C. and Zhao, L. (2021) Progress in Research on the Roles of TGR5 Receptor in Liver Diseases. Scandinavian Journal of Gastroenterology, 56, 717-726. [Google Scholar] [CrossRef] [PubMed]
[38] Gillard, J., Clerbaux, L., Nachit, M., Sempoux, C., Staels, B., Bindels, L.B., et al. (2022) Bile Acids Contribute to the Development of Non-Alcoholic Steatohepatitis in Mice. JHEP Reports, 4, Article ID: 100387. [Google Scholar] [CrossRef] [PubMed]
[39] Pols, T.W.H., Nomura, M., Harach, T., Lo Sasso, G., Oosterveer, M.H., Thomas, C., et al. (2011) TGR5 Activation Inhibits Atherosclerosis by Reducing Macrophage Inflammation and Lipid Loading. Cell Metabolism, 14, 747-757. [Google Scholar] [CrossRef] [PubMed]
[40] Wang, Y., Chen, W., Yu, D., Forman, B.M. and Huang, W. (2011) The G-Protein-Coupled Bile Acid Receptor, Gpbar1 (TGR5), Negatively Regulates Hepatic Inflammatory Response through Antagonizing Nuclear Factor Kappa Light-Chain Enhancer of Activated B Cells (NF-κB) in Mice. Hepatology, 54, 1421-1432. [Google Scholar] [CrossRef] [PubMed]
[41] Biagioli, M., Carino, A., Cipriani, S., Francisci, D., Marchianò, S., Scarpelli, P., et al. (2017) The Bile Acid Receptor GPBAR1 Regulates the M1/M2 Phenotype of Intestinal Macrophages and Activation of GPBAR1 Rescues Mice from Murine Colitis. The Journal of Immunology, 199, 718-733. [Google Scholar] [CrossRef] [PubMed]
[42] Zhou, H., Zhou, S., Shi, Y., Wang, Q., Wei, S., Wang, P., et al. (2021) TGR5/Cathepsin E Signaling Regulates Macrophage Innate Immune Activation in Liver Ischemia and Reperfusion Injury. American Journal of Transplantation, 21, 1453-1464. [Google Scholar] [CrossRef] [PubMed]
[43] Perino, A., Pols, T.W.H., Nomura, M., Stein, S., Pellicciari, R. and Schoonjans, K. (2014) TGR5 Reduces Macrophage Migration through mTOR-Induced C/EBPβ Differential Translation. Journal of Clinical Investigation, 124, 5424-5436. [Google Scholar] [CrossRef] [PubMed]
[44] Perino, A. and Schoonjans, K. (2015) TGR5 and Immunometabolism: Insights from Physiology and Pharmacology. Trends in Pharmacological Sciences, 36, 847-857. [Google Scholar] [CrossRef] [PubMed]
[45] Pellicciari, R., Gioiello, A., Macchiarulo, A., Thomas, C., Rosatelli, E., Natalini, B., et al. (2009) Discovery of 6α-Ethyl-23(s)-Methylcholic Acid (s-EMCA, INT-777) as a Potent and Selective Agonist for the TGR5 Receptor, a Novel Target for Diabesity. Journal of Medicinal Chemistry, 52, 7958-7961. [Google Scholar] [CrossRef] [PubMed]
[46] Gillard, J., Picalausa, C., Ullmer, C., Adorini, L., Staels, B., Tailleux, A., et al. (2022) Enterohepatic Takeda G-Protein Coupled Receptor 5 Agonism in Metabolic Dysfunction-Associated Fatty Liver Disease and Related Glucose Dysmetabolism. Nutrients, 14, Article No. 2707. [Google Scholar] [CrossRef] [PubMed]
[47] Carino, A., Cipriani, S., Marchianò, S., Biagioli, M., Scarpelli, P., Zampella, A., et al. (2017) Gpbar1 Agonism Promotes a Pgc-1α-Dependent Browning of White Adipose Tissue and Energy Expenditure and Reverses Diet-Induced Steatohepatitis in Mice. Scientific Reports, 7, Article No. 13689. [Google Scholar] [CrossRef] [PubMed]
[48] Di Giorgio, C., Urbani, G., Marchianò, S., Biagioli, M., Bordoni, M., Bellini, R., et al. (2025) Liver GPBAR1 Associates with Immune Dysfunction in Primary Sclerosing Cholangitis and Its Activation Attenuates Cholestasis in Abcb4−/− Mice. Liver International, 45, e16235. [Google Scholar] [CrossRef] [PubMed]
[49] Finn, P.D., Rodriguez, D., Kohler, J., Jiang, Z., Wan, S., Blanco, E., et al. (2019) Intestinal TGR5 Agonism Improves Hepatic Steatosis and Insulin Sensitivity in Western Diet-Fed Mice. American Journal of Physiology-Gastrointestinal and Liver Physiology, 316, G412-G424. [Google Scholar] [CrossRef] [PubMed]
[50] Roth, J.D., Feigh, M., Veidal, S.S., Fensholdt, L.K., Rigbolt, K.T., Hansen, H.H., et al. (2018) INT-767 Improves Histopathological Features in a Diet-Induced ob/ob Mouse Model of Biopsy-Confirmed Non-Alcoholic Steatohepatitis. World Journal of Gastroenterology, 24, 195-210. [Google Scholar] [CrossRef] [PubMed]
[51] Comeglio, P., Cellai, I., Mello, T., Filippi, S., Maneschi, E., Corcetto, F., et al. (2018) INT-767 Prevents NASH and Promotes Visceral Fat Brown Adipogenesis and Mitochondrial Function. Journal of Endocrinology, 238, 107-127. [Google Scholar] [CrossRef] [PubMed]
[52] McMahan, R.H., Wang, X.X., Cheng, L.L., Krisko, T., Smith, M., El Kasmi, K., et al. (2013) Bile Acid Receptor Activation Modulates Hepatic Monocyte Activity and Improves Nonalcoholic Fatty Liver Disease. Journal of Biological Chemistry, 288, 11761-11770. [Google Scholar] [CrossRef] [PubMed]
[53] Carino, A., Cipriani, S., Marchianò, S., Biagioli, M., Santorelli, C., Donini, A., et al. (2017) BAR502, a Dual FXR and GPBAR1 Agonist, Promotes Browning of White Adipose Tissue and Reverses Liver Steatosis and Fibrosis. Scientific Reports, 7, Article No. 42801. [Google Scholar] [CrossRef] [PubMed]
[54] Marchianò, S., Biagioli, M., Morretta, E., Di Giorgio, C., Roselli, R., Bordoni, M., et al. (2023) Combinatorial Therapy with BAR502 and UDCA Resets FXR and GPBAR1 Signaling and Reverses Liver Histopathology in a Model of NASH. Scientific Reports, 13, Article No. 1602. [Google Scholar] [CrossRef] [PubMed]
[55] Carino, A., Marchianò, S., Biagioli, M., Fiorucci, C., Zampella, A., Monti, M.C., et al. (2019) Transcriptome Analysis of Dual FXR and GPBAR1 Agonism in Rodent Model of NASH Reveals Modulation of Lipid Droplets Formation. Nutrients, 11, Article No. 1132. [Google Scholar] [CrossRef] [PubMed]
[56] Ding, L., Yang, Q., Zhang, E., Wang, Y., Sun, S., Yang, Y., et al. (2021) Notoginsenoside Ft1 Acts as a TGR5 Agonist but FXR Antagonist to Alleviate High Fat Diet-Induced Obesity and Insulin Resistance in Mice. Acta Pharmaceutica Sinica B, 11, 1541-1554. [Google Scholar] [CrossRef] [PubMed]
[57] Hu, Q., Zhang, W., Wu, Z., Tian, X., Xiang, J., Li, L., et al. (2021) Baicalin and the Liver-Gut System: Pharmacological Bases Explaining Its Therapeutic Effects. Pharmacological Research, 165, Article ID: 105444. [Google Scholar] [CrossRef] [PubMed]
[58] Xue, Y., Wei, Y., Cao, L., Shi, M., Sheng, J., Xiao, Q., et al. (2024) Protective Effects of Scutellaria-Coptis Herb Couple against Non-Alcoholic Steatohepatitis via Activating NRF2 and FXR Pathways in Vivo and in Vitro. Journal of Ethnopharmacology, 318, Article ID: 116933. [Google Scholar] [CrossRef] [PubMed]
[59] Zhang, Z., He, Y., Zhao, M., He, X., Zhou, Z., Yue, Y., et al. (2024) Qinlian Hongqu Decoction Modulates FXR/TGR5/GLP-1 Pathway to Improve Insulin Resistance in NAFLD Mice: Bioinformatics and Experimental Study. ACS Omega, 9, 45447-45466. [Google Scholar] [CrossRef] [PubMed]
[60] Shi, J., Liu, Y., Zhang, Z., Zhong, X., Cao, Y., Ni, H., et al. (2025) Zexie-Baizhu Decoction Ameliorates Non-Alcoholic Fatty Liver Disease through Gut-Adipose Tissue Crosstalk. Journal of Ethnopharmacology, 337, Article ID: 118700. [Google Scholar] [CrossRef] [PubMed]
[61] Zhou, Y., Men, L., Sun, Y., Wei, M. and Fan, X. (2021) Pharmacodynamic Effects and Molecular Mechanisms of Lignans from Schisandra chinensis Turcz. (Baill.), a Current Review. European Journal of Pharmacology, 892, Article ID: 173796. [Google Scholar] [CrossRef] [PubMed]
[62] Gu, M., Feng, Y., Chen, Y., Fan, S. and Huang, C. (2023) Deoxyschizandrin Ameliorates Obesity and Non‐Alcoholic Fatty Liver Disease: Involvement of Dual Farnesyl X Receptor/G Protein‐Coupled Bile Acid Receptor 1 Activation and Leptin Sensitization. Phytotherapy Research, 37, 2771-2786. [Google Scholar] [CrossRef] [PubMed]
[63] Liu, X., Zhou, M., Dai, Z., Luo, S., Shi, Y., He, Z., et al. (2022) Salidroside Alleviates Ulcerative Colitis via Inhibiting Macrophage Pyroptosis and Repairing the Dysbacteriosis‐Associated Th17/Treg Imbalance. Phytotherapy Research, 37, 367-382. [Google Scholar] [CrossRef] [PubMed]
[64] Gao, Z., Zhan, H., Zong, W., Sun, M., Linghu, L., Wang, G., et al. (2023) Salidroside Alleviates Acetaminophen-Induced Hepatotoxicity via Sirt1-Mediated Activation of Akt/Nrf2 Pathway and Suppression of NF-κB/NLRP3 Inflammasome Axis. Life Sciences, 327, Article ID: 121793. [Google Scholar] [CrossRef] [PubMed]
[65] Zhang, J., Zhou, J., He, Z., Xia, Z., Liu, H., Wu, Y., et al. (2025) Salidroside Attenuates NASH through Regulating Bile Acid-FXR/TGR5 Signaling Pathway via Targeting Gut Microbiota. International Journal of Biological Macromolecules, 307, Article ID: 142276. [Google Scholar] [CrossRef] [PubMed]
[66] Shim, Y.Y., Kim, J.H., Cho, J.Y. and Reaney, M.J.T. (2022) Health Benefits of Flaxseed and Its Peptides (Linusorbs). Critical Reviews in Food Science and Nutrition, 64, 1845-1864. [Google Scholar] [CrossRef] [PubMed]
[67] Yang, C., Yang, L., Yang, Y., Wan, M., Xu, D., Pan, D., et al. (2023) Effects of Flaxseed Powder in Improving Non-Alcoholic Fatty Liver by Regulating Gut Microbiota-Bile Acids Metabolic Pathway through FXR/TGR5 Mediating. Biomedicine & Pharmacotherapy, 163, Article ID: 114864. [Google Scholar] [CrossRef] [PubMed]

为你推荐